Anika Therapeutics Inc. (ANIK) Insider Richard Hague Sells 5,250 Shares
Anika Therapeutics Inc. (NASDAQ:ANIK) insider Richard Hague sold 5,250 shares of the stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $54.48, for a total value of $286,020.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Anika Therapeutics Inc. (ANIK) traded down $0.38 on Friday, reaching $54.74. The company’s stock had a trading volume of 51,309 shares, compared to its average volume of 99,329. The firm has a market capitalization of $803.17, a P/E ratio of 25.72, a price-to-earnings-growth ratio of 2.88 and a beta of 1.47. Anika Therapeutics Inc. has a 12-month low of $41.64 and a 12-month high of $60.29.
Anika Therapeutics (NASDAQ:ANIK) last released its earnings results on Wednesday, October 25th. The biotechnology company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.05. The firm had revenue of $27.18 million during the quarter, compared to the consensus estimate of $27.44 million. Anika Therapeutics had a return on equity of 13.40% and a net margin of 28.23%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.59 earnings per share. analysts forecast that Anika Therapeutics Inc. will post 1.9 EPS for the current year.
A number of equities research analysts have weighed in on ANIK shares. BidaskClub upgraded Anika Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 8th. Barrington Research upped their target price on Anika Therapeutics from $53.00 to $57.00 and gave the stock an “outperform” rating in a research report on Friday, October 27th.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Stock Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related stocks with our FREE daily email newsletter.